雪榕生物 reported revenue of ¥1.16B for the period ended 2026-06-30, +46.2% year on year. Net income was ¥0.01B, a 1.2% net margin on a 17.2% gross margin. The largest revenue line is 食用菌 at 99% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.16B | +46.2% |
| Gross profit | ¥0.20B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | — |
| Gross margin | 17.2% | Net margin 1.2% |
| Revenue Q/Q | -29.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 食用菌 | ¥1.15B | 99.2% |
| 培养基 | ¥0.01B | 0.8% |
| 其他 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.96B | 82.8% |
| R&D | ¥0.00B | 0.2% |
| SG&A | ¥0.08B | 7.0% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥3.53B |
| Total liabilities | ¥1.99B |
| Shareholders' equity | ¥1.53B |
| Equity / assets | 43.5% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | 1610% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯 ・ 世名科技 ・ 辰安科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies